ArticleScientific reports2025
Intestinal metabolomics analysis reveals lysophosphatidylcholine is the key regulatory metabolite in mouse models of necrotizing enterocolitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrotizing enterocolitis (NEC) is a severe intestinal emergency in neonates. This study explored NEC-related biomarkers by metabolomics to provide new insights for the clinical therapy of NEC. A mouse NEC model was induced by lipopolysaccharide (LPS), hypoxia, and cold stress. Hematoxylin and eosin (H&E), Ki-67, and TUNEL staining were used to detect the pathological changes in mouse intestinal tissues; the intestinal mRNA expression levels of inflammatory-associated cytokines were detected using qRT-PCR. Intestinal content samples of NEC mice were analyzed by metabolomics. Lysophosphatidylcholine (15:0/0:0) (lysoPC) effects on NEC were explored in both in vivo and in vitro models. NEC mice showed significantly decreased body weight and survival rate, shortened intestinal length, and significant pathological changes. Moreover, in NEC mice, intestinal cell proliferation was reduced, apoptosis was increased, and IL-1β, IL-6, and TNF-α mRNA expressions dramatically increased while IL-10 mRNA expression was reduced. According to the metabolomics results, lysoPC level was significantly reduced in the intestinal contents of the NEC group. Supplementing lysoPC alleviated the pathological symptoms in NEC mice and reversed formate-induced injury in human intestinal epithelial cell line HIEC6. LysoPC supplementation alleviates the pathological symptoms of NEC mice, which is a promising novel option for the clinical treatment of NEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.